With a stronger balance sheet secured, Cavendish believes IXICO PLC (AIM:IXI, OTC:PHYOF) shares offer significant upside for investors.
The med-tech firm, which specialises in AI-driven imaging for neurological disorders, has repositioned itself for sustainable revenue growth following a challenging period.
Cavendish notes that October's £4 million investment round will support expansion into larger therapy areas and a return revenue growth and enable it to reach profitability.
IXICO is a leading player in neuroimaging for clinical trials, particularly in Huntington’s disease. It recently announced a key milestone in its work with the Huntington’s Disease Imaging Harmonisation consortium, successfully analysing over 6,000 MRI scans to refine biomarkers for disease staging.
These biomarkers could help improve patient selection and trial design, making IXICO an attractive partner for pharmaceutical firms conducting research in neurodegenerative diseases.
The company’s IXIQ.Ai platform, which leverages artificial intelligence to analyse brain imaging, has shown strong potential beyond Huntington’s disease.
Cavendish highlights that IXICO’s technology could be applied to Alzheimer’s and Parkinson’s disease, two areas with growing demand for precision medicine. Recent regulatory approvals for Alzheimer’s treatments have renewed industry interest, opening opportunities for IXICO to expand its services.
IXICO’s financial position has also improved. The company raised additional funds to support its technology development and strategic partnerships. Huntington’s disease accounts for over half of IXICO’s clinical trial order book, with multiple long-term contracts in place.
Cavendish sees this as a stable foundation for revenue growth while the company broadens its reach into other neurological conditions.
Despite a broader slowdown in clinical trial initiations, Cavendish expects IXICO to benefit as the market normalises. The company’s ability to offer advanced imaging biomarkers positions it well to secure contracts with major pharmaceutical firms.
Cavendish also points to IXICO’s established industry relationships and its participation in major consortia as key strengths.
Overall, Cavendish maintains a positive outlook on IXICO, citing its improved financial footing, strategic positioning in high-demand therapy areas, and the potential for long-term growth in the neuroimaging sector.
"With a stronger balance sheet secured, we believe IXICO shares offer significant upside for investors," investors were told.